Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
07 Août 2023 - 2:00PM
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company
focused on discovering and developing transformative therapeutics
for patients, announces the appointment of Roger Waltzman, M.D. as
its Chief Medical Officer, effective August 7, 2023.
Jeffrey Meckler, Indaptus’ CEO commented, “Roger’s deep
experience in drug development, particularly in the field of
immuno-oncology, and his time as an officer at development and
clinical-stage companies makes him an ideal candidate to assume the
position of chief medical officer at Indaptus. We look forward to
the rapid impact he will make on our development programs, as well
as his invaluable contributions to the ongoing advancement of our
Decoy platform as it continues in Phase 1 trials.”
Dr. Waltzman joins Indaptus from Molecular Templates, a publicly
traded biotechnology company focused on discovery and development
of immunotoxins. Prior, he served in the c-suite as Chief Medical
Officer at Rgenix, Inc. (now Inspirna, Inc) and as Chief Scientific
Officer at Jaguar Health. He spent nine years at Novartis, where he
served in several leadership positions, including Global Program
Head for Tropical Medicines and Clinical Program Head for several
key brands, such as Glivec, Tasigna, and Jakavi.Dr. Waltzman spent
the early part of his career as a medical oncologist, serving in
two of New York City’s premiere hospitals, Mount Sinai Medical
System and St. Vincent’s Hospital. He earned his M.D. degree at
Brown University, where he also earned a bachelor’s degree in
American Literature and holds a Master’s in Business Administration
from Columbia University Business School.
“Indaptus has taken a unique approach to immuno-oncology, and
the preclinical results of its Decoy program have been extremely
encouraging. As the Company continues its INDP-D101 trial and
beyond, I am enthusiastic about making a significant impact on the
development program and working closely with management to advance
this innovative platform for the benefit of patients,” added Dr.
Waltzman.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of
immunotherapy advances. The Company’s novel approach is based on
the hypothesis that efficient activation of both innate and
adaptive immune cells and pathways and associated anti-tumor and
anti-viral immune responses will require a multi-targeted package
of immune system-activating signals that can be administered safely
intravenously (i.v.). Indaptus’ patented technology is composed of
single strains of attenuated and killed, non-pathogenic,
Gram-negative bacteria producing a multiple Toll-like receptor
(TLR) agonist Decoy platform. The products are designed to have
reduced i.v. toxicity, but largely uncompromised ability to prime
or activate many of the cells and pathways of innate and adaptive
immunity. Decoy products represent an antigen-agnostic technology
that have produced single-agent activity against metastatic
pancreatic and orthotopic colorectal carcinomas, single agent
eradication of established antigen-expressing breast carcinoma, as
well as combination-mediated eradication of established
hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard
pre-clinical models, including syngeneic mouse tumors and human
tumor xenografts. In pre-clinical studies, tumor eradication was
observed with Decoy products in combination with anti-PD-1
checkpoint therapy, low-dose chemotherapy, a non-steroidal
anti-inflammatory drug, or an approved, targeted antibody.
Combination-based tumor eradication in pre-clinical models produced
innate and adaptive immunological memory, involved activation of
both innate and adaptive immune cells, and was associated with
induction of innate and adaptive immune pathways in tumors after
only one i.v. dose of Decoy product, with associated “cold” to
“hot” tumor inflammation signature transition. IND-enabling,
nonclinical toxicology studies demonstrated safe i.v.
administration without sustained induction of hallmark biomarkers
of cytokine release syndrome, possibly due to passive targeting to
liver, spleen, and tumor, followed by rapid elimination of the
product. Indaptus’ Decoy products have also produced significant
single agent activity against chronic hepatitis B virus (HBV) and
chronic human immunodeficiency virus (HIV) infections in
pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements with the
meaning of the Private Securities Litigation Reform Act. These
include statements regarding management’s expectations, beliefs and
intentions regarding, among other things: our expectations and
plans regarding the Phase 1 clinical trial of Decoy20, including
the timing and design thereof; the plans and objectives of
management for future operations; our research and development
activities and costs; the sufficiency of our cash, cash equivalents
and marketable securities to fund our ongoing activities and our
cash management strategy; and our assessment of financing options
to support our corporate strategy. Forward-looking statements can
be identified by the use of forward-looking words such as
“believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”,
“might”, “seek”, “target”, “will”, “project”, “forecast”,
“continue” or “anticipate” or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. Because
forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to risks and
uncertainties that could cause our actual results to differ
materially from any future results expressed or implied by the
forward-looking statements. Many factors could cause actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to the following: our limited operating history; the
need for, and our ability to raise, additional capital given our
lack of current cash flow; our clinical and preclinical
development, which involves a lengthy and expensive process with an
uncertain outcome; our incurrence of significant research and
development expenses and other operating expenses, which may make
it difficult for us to attain profitability; our pursuit of a
limited number of research programs, product candidates and
specific indications and failure to capitalize on product
candidates or indications that may be more profitable or have a
greater likelihood of success; our ability to obtain and maintain
regulatory approval of any product candidate; the market acceptance
of our product candidates; our reliance on third parties to conduct
our preclinical studies and clinical trials and perform other
tasks; our reliance on third parties for the manufacture of our
product candidates during clinical development; our ability to
successfully commercialize Decoy20 or any future product
candidates; our ability to obtain or maintain coverage and adequate
reimbursement for our products; the impact of legislation and
healthcare reform measures on our ability to obtain marketing
approval for and commercialize Decoy20 and any future product
candidates; product candidates of our competitors that may be
approved faster, marketed more effectively, and better tolerated
than our product candidates; our ability to adequately protect our
proprietary or licensed technology in the marketplace; the impact
of, and costs of complying with healthcare laws and regulations,
and our failure to comply with such laws and regulations;
information technology system failures, cyberattacks or
deficiencies in our cybersecurity; and unfavorable global economic
conditions. These and other important factors discussed under the
caption “Risk Factors” included in our Quarterly Report on Form
10-Q for the quarter ended March 31, 2023 filed with the SEC on May
11, 2023, our most recent Annual Report on Form 10-K filed with the
SEC on March 17, 2023, and our other filings with the SEC, could
cause actual results to differ materially from those indicated by
the forward-looking statements made in this press release. All
forward-looking statements speak only as of the date of this press
release and are expressly qualified in their entirety by the
cautionary statements included in this press release. We undertake
no obligation to update or revise forward-looking statements to
reflect events or circumstances that arise after the date made or
to reflect the occurrence of unanticipated events, except as
required by applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:CORE IRLouie
Tomalouie@coreir.com
Media Contact:CORE IRJules
Abrahamjulesa@coreir.com 917-885-7378
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e634a5e4-e166-47d5-a4e1-377820a4542d
Indaptus Therapeutics (NASDAQ:INDP)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Indaptus Therapeutics (NASDAQ:INDP)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024